Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2019 | Urothelial carcinoma: apatorsen plus docetaxel does not provide significant value

Petros Grivas, MD, PhD, Seattle Cancer Care Alliance, Seattle, WA, discusses a trial comparing apatorsen plus docetaxel versus docetaxel alone in platinum-resistant metastatic urothelial carcinoma (NCT01780545). Dr Grivas points out that it was an important study contributing to the literature, but that the combination tested did not provide enough efficacy. This interview took place at the European Society for Medical Oncology (ESMO) 2019 congress in Barcelona, Spain.